The most common ANA pattern in Hashimoto’s thyroiditis is speckled, accounting for about 38% of positive results. The second most common is homogeneous, at roughly 28%. However, most people with Hashimoto’s don’t test positive for ANA at all, and a positive result doesn’t necessarily mean you have a second autoimmune disease.
The Two Main ANA Patterns in Hashimoto’s
When labs report an ANA result, they describe both the titer (how concentrated the antibodies are) and the pattern (how the antibodies light up cells under a fluorescent microscope). Each pattern reflects a different type of antibody targeting different parts of the cell nucleus.
In Hashimoto’s patients who do test ANA-positive, the speckled pattern (classified as AC-4/5 in lab terminology) shows up most often, at about 37.6% of cases. This pattern means the antibodies are binding to proteins scattered throughout the nucleus. It’s also the most common pattern in the general population, so on its own it’s relatively nonspecific.
The homogeneous pattern (AC-1) is the next most frequent, appearing in about 28% of ANA-positive Hashimoto’s cases. This pattern means the antibodies are targeting the entire nucleus evenly. What’s notable is that the homogeneous pattern becomes more dominant as thyroid antibody levels climb. In other words, the higher your TPO or thyroglobulin antibodies, the more likely your ANA will show a homogeneous pattern rather than a speckled one.
How Often Hashimoto’s Patients Test ANA-Positive
Not everyone with Hashimoto’s will have a positive ANA. The rate depends heavily on how active the thyroid autoimmunity is, measured by the level of thyroid-specific antibodies like TPO antibodies and thyroglobulin antibodies.
For people with low TPO antibody levels (under 34 IU/mL), only about 6% test ANA-positive. That rate climbs to 13% when TPO antibodies are moderately elevated and reaches roughly 16.5% when TPO antibodies are high (above 100 IU/mL). Thyroglobulin antibodies follow a similar trend: ANA positivity jumps from about 6% at low levels to 19% at levels above 500 IU/mL.
A large study using NHANES data found the same dose-response relationship. People with very high TPO antibodies (above 600 IU/mL) were nearly three times more likely to be ANA-positive than those with normal levels. The risk at moderate levels was about 50% higher than baseline. So the more aggressive the thyroid autoimmunity, the more likely the immune system is producing antibodies that also react to cell nuclei.
Why Hashimoto’s Triggers ANA Production
Hashimoto’s is an organ-specific autoimmune disease, meaning the immune attack is primarily aimed at the thyroid gland. But the immune activation doesn’t always stay neatly contained. In Hashimoto’s, certain immune cells stimulate antibody-producing cells to create not just thyroid-specific antibodies but also broader antinuclear antibodies. The chronic inflammation within the thyroid gland, driven by both antibodies and inflammatory signaling molecules, can essentially spill over into a more generalized immune response.
This is why people with higher thyroid antibody levels are more likely to have a positive ANA. The more intense the autoimmune process in the thyroid, the more likely the immune system is to produce “bystander” antibodies that target nuclear material in cells throughout the body. People who are ANA-positive tend to have higher TSH levels as well, suggesting more thyroid dysfunction overall.
What a Positive ANA Means (and Doesn’t Mean)
If you have Hashimoto’s and your ANA comes back positive, it doesn’t automatically mean you have lupus, Sjögren’s syndrome, or another systemic autoimmune condition. About one-third of people with autoimmune thyroid disease will test ANA-positive, but the majority of them have no additional autoimmune diagnosis.
That said, the overlap is real. Among ANA-positive patients with autoimmune thyroid disease, roughly 10% have anti-Ro antibodies (linked to Sjögren’s syndrome), 12% have anti-dsDNA antibodies (linked to lupus), and 12% have anticardiolipin antibodies (linked to clotting disorders). About 9% of ANA-positive thyroid patients meet the full diagnostic criteria for Sjögren’s syndrome, making it the most common overlap condition. Lupus features appear in a smaller percentage, and limited systemic sclerosis is occasionally seen as well, particularly when anticentromere antibodies are present.
The pattern itself offers some clues. A homogeneous pattern at higher titers is more closely associated with lupus-related antibodies, while a speckled pattern is less specific and often found in people without any systemic disease. A low-titer speckled ANA in someone with well-characterized Hashimoto’s is usually considered a reflection of generalized immune activation rather than evidence of a second condition. Higher titers and specific extractable nuclear antigen antibodies are what typically prompt further investigation into overlapping autoimmune diseases.
How Titer Levels Factor In
The ANA titer, reported as a ratio like 1:80 or 1:160, tells you how diluted the blood sample can be and still show a positive result. Higher titers mean more antibodies are present. In isolated Hashimoto’s without a coexisting systemic disease, ANA titers tend to be low, typically 1:80 or 1:160. These low-positive results are common even in healthy people and are generally not considered clinically significant on their own.
When titers reach 1:320 or higher, or when they come with specific antibody subtypes like anti-dsDNA or anti-Ro, the likelihood of a true systemic autoimmune condition increases substantially. In studies of thyroid patients with these higher-specificity antibodies, more than 25% eventually met classification criteria for conditions like lupus or limited systemic sclerosis. So the combination of pattern, titer, and specific antibody subtypes matters far more than any single ANA result in isolation.